ArticleBlood cancer discovery2022
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Article in Blood cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 70 citations in OpenAlex.
- Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications.International journal of laboratory hematology · 2026Review
- Clinical management of clonal hematopoiesis.Cancer · 2026Review
- Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.Leukemia · 2026Article
- Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.Blood neoplasia · 2026Article
- Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.Bone marrow transplantation · 2026Article
- Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation.HemaSphere · 2026Article
- Diffuse large B‑cell lymphoma followed by myelodysplastic syndrome with TP53 mutation: a case report and literature review.Frontiers in oncology · 2026Article
- Pre-Infusion Host-Marrow Vulnerability in CD19- and BCMA-Directed CAR T-Cell Therapy: Clonal Hematopoiesis, Hematotoxicity, and Therapy-Related Myeloid Neoplasia.Cancer management and research · 2026Review
- Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances.Journal of translational medicine · 2025Review
- Demystifying the diagnosis and management of ICUS, CHIP, and CCUS.Hematology. American Society of Hematology. Education Program · 2025Review
- CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.Research square · 2025Article
- Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy.Journal for immunotherapy of cancer · 2025Article
- Article
- Article
- Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.Haematologica · 2025Review
- Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma.Journal of hematology · 2025Article
- Clonal Hematopoiesis: Impact on Health and Disease.Hematological oncology · 2025Review
- TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2025Review
- Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.Annals of hematology · 2025Article
Corrections and comments
- Commented on by
- Comment on
- Expression of concern
Authors and funding
39 authors at 2 institutions in 1 country.
Funding
Abstract
To explore the role of clonal hematopoiesis (CH) in chimeric antigen receptor (CAR) T-cell therapy outcomes, we performed targeted deep sequencing on buffy coats collected during the 21 days before lymphodepleting chemotherapy from 114 large B-cell lymphoma patients treated with anti-CD19 CAR T cells. We detected CH in 42 (36.8%) pretreatment samples, most frequently in PPM1D (19/114) and TP53 (13/114) genes. Grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS) incidence was higher in CH-positive patients than CH-negative patients (45.2% vs. 25.0%, P = 0.038). Higher toxicities with CH were primarily associated with DNMT3A, TET2, and ASXL1 genes (DTA mutations). Grade ≥3 ICANS (58.9% vs. 25%, P = 0.02) and ≥3 cytokine release syndrome (17.7% vs. 4.2%, P = 0.08) incidences were higher in DTA-positive than in CH-negative patients. The estimated 24-month cumulative incidence of therapy-related myeloid neoplasms after CAR T-cell therapy was higher in CH-positive than CH-negative patients [19% (95% CI, 5.5-38.7) vs. 4.2% (95% CI, 0.3-18.4), P = 0.028]. SIGNIFICANCE: Our study reveals that CH mutations, especially those associated with inflammation (DNMT3A, TET2, and ASXL1), are associated with severe-grade neurotoxicities in lymphoma patients receiving anti-CD19 CAR T-cell therapy. Further studies to investigate the mechanisms and interventions to improve toxicities in the context of CH are warranted. See related content by Uslu and June, p. 382. This article is highlighted in the In This Issue feature, p. 369.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.